Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients

References

• Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;18:463–82. doi:10.1038/nrclinonc.2017.43.
   Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206. doi:10.1200/JCO.2009.23.4799. PMID:19917835.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously untreated melanoma without braf mutation. N Engl J Med. 2015;372:320–30. doi:10.1056/NEJMoa1412082. PMID:25399552.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–32. doi:10.1056/NEJMoa1503093. PMID:25891173.
   PubMed Web of Science ®Google Scholar
• Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D, Dummer R, Robert C, Marquez-Rodas I, McNeil C, et al. Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials. JAMA Oncol. 2017;3:1511–9. doi:10.1001/jamaoncol.2017.1588. PMID:28662232.
   PubMed Web of Science ®Google Scholar
• Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, Giugliano FM, Sandomenico F, Petrillo A, Curvietto M, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014;3:e28780. doi:10.4161/onci.28780. PMID:25083318.
   PubMed Web of Science ®Google Scholar
• Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA, Ng AK, Hodi FS, Schoenfeld JD. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015;4:e1046028. doi:10.1080/2162402X.2015.1046028. PMID:26451318.
   PubMed Web of Science ®Google Scholar
• Kropp LM, De Los Santos JF, McKee SB, Conry RM. Radiotherapy to control limited melanoma progression following ipilimumab. J Immunother. 2016;39:373–8. doi:10.1097/CJI.0000000000000142. PMID:27662339.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–31. doi:10.1056/NEJMoa1112824. PMID:22397654.
   PubMed Web of Science ®Google Scholar
• Choong ES, Lo S, Drummond M, Fogarty GB, Menzies AM, Guminski A, Shivalingam B, Clarke K, Long GV, Hong AM. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. Eur J Cancer. 2017;75:169–78. doi:10.1016/j.ejca.2017.01.007. PMID:28236768.
   PubMed Web of Science ®Google Scholar
• Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, et al. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Br J Cancer. 2017;116:1558–63. doi:10.1038/bjc.2017.142. PMID:28524161.
   PubMed Web of Science ®Google Scholar
• Ahmed KA, Stallworth DG, Kim Y, Johnstone PA, Harrison LB, Caudell JJ, Yu HH, Etame AB, Weber JS, Gibney GT. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol. 2016;27:434–41. doi:10.1093/annonc/mdv622. PMID:26712903.
   PubMed Web of Science ®Google Scholar
• Gaudy-Marqueste C, Dussouil AS, Carron R, Troin L, Malissen N, Loundou A, Monestier S, Mallet S, Richard MA, Regis JM, et al. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. Eur J Cancer. 2017;84:44–54. doi:10.1016/j.ejca.2017.07.017. PMID:28783540.
   PubMed Web of Science ®Google Scholar
• Aboudaram A, Modesto A, Chaltiel L, Gomez-Roca C, Boulinguez S, Sibaud V, Delord JP, Chira C, Delannes M, Moyal E, et al. Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: A safe and effective combination. Melanoma Res. 2017;27:485–91. doi:10.1097/CMR.0000000000000386. PMID:28858075.
   PubMed Web of Science ®Google Scholar
• Doyen J, Picard A, Naghavi AO, Thyss A, Passeron T, Lacour JP, Montaudie H. Clinical outcomes of metastatic melanoma treated with checkpoint inhibitors and multisite radiotherapy. JAMA Dermatol. 2017;153:1056–59. doi:10.1001/jamadermatol.2017.2222. PMID:28746710.
   PubMed Web of Science ®Google Scholar
• Liniker E, Menzies AM, Kong BY, Cooper A, Ramanujam S, Lo S, Kefford RF, Fogarty GB, Guminski A, Wang TW, et al. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology. 2016;5:e1214788. doi:10.1080/2162402X.2016.1214788. PMID:27757312.
   PubMed Web of Science ®Google Scholar
• Qian JM, Yu JB, Kluger HM, Chiang VL. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer. 2016;122:3051–8. doi:10.1002/cncr.30138. PMID:27285122.
   PubMedGoogle Scholar
• Koo T, Kim IA. Radiotherapy and immune checkpoint blockades: a snapshot in 2016. Radiat Oncol J. 2016;34:250–9. doi:10.3857/roj.2016.02033. PMID:28030901.
   PubMed Web of Science ®Google Scholar
• Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13:473–86. doi:10.1038/nrclinonc.2016.58. PMID:27141885.
   PubMed Web of Science ®Google Scholar
• Reddy SB, Possick JD, Kluger HM, Galan A, Han D. Sarcoidosis following anti-PD-1 and anti-CTLA-4 therapy for metastatic melanoma. J Immunother. 2017;40:307–11. doi:10.1097/CJI.0000000000000181. PMID:28737620.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, Postow MA, Weinstein A, Lucas AS, Ciccolini KT, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PDL-1. Cancer Immunol Res. 2016;4:383–9. doi:10.1158/2326-6066.CIR-15-0123. PMID:26928461.
   PubMed Web of Science ®Google Scholar
• Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, Luiten RM. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33:773–81. doi:10.1200/JCO.2014.57.4756. PMID:25605840.
   PubMed Web of Science ®Google Scholar
• De Wolf K, Kruse V, Sundahl N, van Gele M, Chevolet I, Speeckaert R, Brochez L, Ost P. A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response. J Transl Med. 2017;15:21. doi:10.1186/s12967-017-1123-x. PMID:28137295.
   PubMed Web of Science ®Google Scholar
• Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res. 2017;77:839–50. doi:10.1158/0008-5472.CAN-15-3142. PMID:27821490.
   PubMed Web of Science ®Google Scholar
• Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, Deweese TL, Drake CG. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2015;3:345–55. doi:10.1158/2326-6066.CIR-14-0196. PMID:25527358.
   PubMed Web of Science ®Google Scholar
• Twyman-Saint\sVictor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373–7. doi:10.1038/nature14292. PMID:25754329.
   PubMed Web of Science ®Google Scholar
• Lakin N, Rulach R, Nowicki S, Kurian KM. Current advances in checkpoint inhibitors: Lessons from non-central nervous system cancers and potential for glioblastoma. Front Oncol. 2017;7:141. doi:10.3389/fonc.2017.00141. PMID:28730140.
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618. doi:10.1038/ncomms15618. PMID:28598415.
   PubMed Web of Science ®Google Scholar
• Moreau S, Saiag P, Aegerter P, Bosset D, Longvert C, Helias-Rodzewicz Z, Marin C, Peschaud F, Chagnon S, Zimmermann U, et al. Prognostic value of BRAF (V600) mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol. 2012;19:4314–21. doi:10.1245/s10434-012-2457-5. PMID:22772867.
   PubMed Web of Science ®Google Scholar
• Helias-Rodzewicz Z, Funck-Brentano E, Terrones N, Beauchet A, Zimmermann U, Marin C, Saiag P, Emile JF. Variation of mutant allele frequency in NRAS Q61 mutated melanomas. BMC Dermatol. 2017;17:9. doi:10.1186/s12895-017-0061-x. PMID:28668077.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34:1510–7. doi:10.1200/JCO.2015.64.0391. PMID:26951310.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised recist guideline (version 1.1). Eur J Cancer. 2009;45:228–47. doi:10.1016/j.ejca.2008.10.026. PMID:19097774.
   PubMed Web of Science ®Google Scholar
• World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4. doi:10.1001/jama.2013.281053. PMID:24141714.
   PubMed Web of Science ®Google Scholar